HK1050204B - 類升糖素肽-2分子 - Google Patents

類升糖素肽-2分子

Info

Publication number
HK1050204B
HK1050204B HK03100905.1A HK03100905A HK1050204B HK 1050204 B HK1050204 B HK 1050204B HK 03100905 A HK03100905 A HK 03100905A HK 1050204 B HK1050204 B HK 1050204B
Authority
HK
Hong Kong
Prior art keywords
glucagon
analogs
peptide
synthesis
identified
Prior art date
Application number
HK03100905.1A
Other languages
English (en)
Other versions
HK1050204A1 (en
Inventor
Daniel J Drucker
Martin Sumner-Smith
Anna E Crivici
Original Assignee
Ontario Inc 1149336
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24530501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1050204(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ontario Inc 1149336, Nps Pharma Inc filed Critical Ontario Inc 1149336
Publication of HK1050204A1 publication Critical patent/HK1050204A1/xx
Publication of HK1050204B publication Critical patent/HK1050204B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK03100905.1A 1996-04-12 2003-02-07 類升糖素肽-2分子 HK1050204B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63127396A 1996-04-12 1996-04-12

Publications (2)

Publication Number Publication Date
HK1050204A1 HK1050204A1 (en) 2003-06-13
HK1050204B true HK1050204B (zh) 2011-09-23

Family

ID=24530501

Family Applications (3)

Application Number Title Priority Date Filing Date
HK00105089A HK1033324A1 (en) 1996-04-12 2000-08-15 Glucagon-like peptide-2 analogs
HK11101311.7A HK1147761A1 (en) 1996-04-12 2003-02-07 Glucagon-like peptide-2 analogs
HK03100905.1A HK1050204B (zh) 1996-04-12 2003-02-07 類升糖素肽-2分子

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK00105089A HK1033324A1 (en) 1996-04-12 2000-08-15 Glucagon-like peptide-2 analogs
HK11101311.7A HK1147761A1 (en) 1996-04-12 2003-02-07 Glucagon-like peptide-2 analogs

Country Status (16)

Country Link
EP (5) EP2009024A1 (zh)
JP (3) JP4148994B2 (zh)
CN (1) CN1268640C (zh)
AT (2) ATE478892T1 (zh)
AU (1) AU733857B2 (zh)
BR (1) BRPI9708566B8 (zh)
CA (1) CA2251576C (zh)
DE (2) DE60142885D1 (zh)
DK (2) DK1231219T3 (zh)
ES (2) ES2351661T3 (zh)
FR (1) FR13C0013I2 (zh)
HK (3) HK1033324A1 (zh)
LU (1) LU92153I2 (zh)
NZ (1) NZ332281A (zh)
PT (2) PT906338E (zh)
WO (1) WO1997039031A1 (zh)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
DK1231219T3 (da) 1996-04-12 2010-12-20 Ontario Inc 1149336 GLucagon-lignende peptid-2 analoger
US5952301A (en) * 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
CA2236519C (en) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
CA2289652C (en) * 1997-05-16 2012-02-28 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
EP1060192A2 (en) * 1998-02-27 2000-12-20 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
AU7421598A (en) * 1998-05-11 1999-11-29 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
WO2002022151A2 (en) 2000-09-18 2002-03-21 Osteometer Bio Tech A/S Use of glp-1 and flp-2 peptides for treatment of bone disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
ATE502665T1 (de) 2003-02-04 2011-04-15 Novo Nordisk As Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
ES2330335T3 (es) * 2003-08-21 2009-12-09 Novo Nordisk A/S Purificacion de peptidos tipo glucagon.
CA2552043A1 (en) 2004-01-21 2005-08-04 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
EP1809318B1 (en) 2004-11-01 2013-06-12 NPS Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
NZ591178A (en) 2005-05-04 2012-06-29 Zealand Pharma As Glucagon-like-peptide-2 (glp-2) analogues
CN100418983C (zh) * 2005-05-11 2008-09-17 中国药科大学 人胰高血糖素相关肽-2类似物
NZ576260A (en) 2006-11-08 2012-04-27 Zealand Pharma As GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES comprising one of more substitutions as compared to h[Gly2]GLP-2
CN101824087A (zh) * 2009-03-05 2010-09-08 连云港恒邦医药科技有限公司 胰高血糖素样肽-2类似物及其制备方法和用途
EP2311486A1 (en) * 2009-10-07 2011-04-20 Nestec S.A. GLP-2 for use in intestine and muscle recovery
EP2314616A1 (en) * 2009-10-23 2011-04-27 Ferring B.V. Peptidic GLP-2 agonists
US20120264684A1 (en) * 2009-10-30 2012-10-18 Yasuhiro Kajihara Glycosylated Form of Antigenic GLP-1 Analogue
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
JP2013526535A (ja) * 2010-05-11 2013-06-24 エヌピーエス ファーマシューティカルズ インコーポレイテッド 腎機能障害または肝機能障害の治療または予防のための方法
WO2012131109A2 (en) 2011-04-01 2012-10-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaft e.V. Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders
CN102924589B (zh) * 2011-08-11 2016-08-24 中肽生化有限公司 胰高血糖素样肽-2(glp-2)的类似物及其制备方法和用途
BR112014027345A2 (pt) 2012-05-03 2019-09-03 Zealand Pharma As análogos de peptídeo 2 semelhante ao glucagon (glp-2)
CN103159848B (zh) * 2013-01-06 2015-11-25 中国人民解放军第四军医大学 人胰高血糖素样肽-2二串体蛋白及其制备方法
EP2968469A4 (en) 2013-03-15 2016-08-31 Longevity Biotech Inc PEPTIDES COMPRISING NON-ENDOGENIC AMINO ACIDS AND METHODS OF MAKING AND USING SAME
WO2018069442A1 (en) * 2016-10-12 2018-04-19 University Of Copenhagen Peptide dual agonists of gipr and glp2r
MX2019006486A (es) 2016-12-09 2019-08-01 Zealand Pharma As Agonistas duales acilados de glp-1/glp-2.
WO2019086559A1 (fr) 2017-10-31 2019-05-09 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2020020904A1 (en) 2018-07-23 2020-01-30 Zealand Pharma A/S Therapeutic uses of glp-2 agonists
EP3628683A1 (en) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP3628682A1 (en) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP3924369A1 (en) 2019-02-11 2021-12-22 OPKO Biologics Ltd. Long-acting glp-2 analogs
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
WO2021198195A1 (en) 2020-03-30 2021-10-07 Zealand Pharma A/S Agonist combination
KR20240134130A (ko) * 2021-12-17 2024-09-06 바이난 바이오테크 에이피에스 Gipr 및 glp2r의 펩티드 이중 작용제

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5186117A (en) 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
GB1575343A (en) 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
US4529561A (en) 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
GB2046092B (en) 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
US4452747A (en) 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5009956A (en) 1987-02-24 1991-04-23 Univ Minnesota Phospholipase A2-resistant liposomes
US4927637A (en) 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
JP2961045B2 (ja) 1993-02-24 1999-10-12 日清製粉株式会社 腸管粘膜増強促進剤
CA2137206A1 (en) 1993-12-09 1995-06-10 John A. Galloway Glucagon-like insulinotropic peptides, compositions and methods
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
DE69740176D1 (de) 1996-03-01 2011-05-26 Novo Nordisk As Appetithemmendes Peptid, Zusammensetzung und Verwendung
DK1231219T3 (da) 1996-04-12 2010-12-20 Ontario Inc 1149336 GLucagon-lignende peptid-2 analoger
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity

Also Published As

Publication number Publication date
WO1997039031A1 (en) 1997-10-23
ES2188929T3 (es) 2003-07-01
JP4148994B2 (ja) 2008-09-10
DK0906338T3 (da) 2003-03-03
EP1231219A1 (en) 2002-08-14
DE69716905D1 (de) 2002-12-12
EP2218734B1 (en) 2013-06-05
EP2218734A3 (en) 2010-10-13
DE60142885D1 (de) 2010-10-07
CA2251576C (en) 2012-08-21
BRPI9708566A (pt) 2000-01-04
EP1231219B1 (en) 2010-08-25
JP5019466B2 (ja) 2012-09-05
HK1033324A1 (en) 2001-08-24
AU2500297A (en) 1997-11-07
JP2007204491A (ja) 2007-08-16
PT906338E (pt) 2003-03-31
CA2251576A1 (en) 1997-10-23
FR13C0013I2 (fr) 2013-08-16
HK1147761A1 (en) 2011-08-19
JP2000511881A (ja) 2000-09-12
EP2275438A1 (en) 2011-01-19
EP2218734A2 (en) 2010-08-18
ATE478892T1 (de) 2010-09-15
ES2351661T3 (es) 2011-02-09
PT1231219E (pt) 2010-11-30
EP0906338B1 (en) 2002-11-06
CN1244872A (zh) 2000-02-16
CN1268640C (zh) 2006-08-09
EP2009024A1 (en) 2008-12-31
FR13C0013I1 (zh) 2013-05-04
NZ332281A (en) 2000-03-27
EP0906338A1 (en) 1999-04-07
AU733857B2 (en) 2001-05-31
BRPI9708566B8 (pt) 2022-01-18
HK1050204A1 (en) 2003-06-13
DK1231219T3 (da) 2010-12-20
ATE227309T1 (de) 2002-11-15
JP4149497B2 (ja) 2008-09-10
DE69716905T2 (de) 2003-07-24
BR9708566B1 (pt) 2012-09-04
JP2008184465A (ja) 2008-08-14
LU92153I2 (fr) 2013-04-19

Similar Documents

Publication Publication Date Title
FR13C0013I1 (zh)
HUT64298A (en) Method for producing 9-amino-7-(substituted)-6-demethyl-6-desoxy-0tetracycline derivatives and medical preparatives containing them
AU681198B2 (en) Preparation of 3,4,4-trisubstituted-piperidinyl-N- alkylcarboxylates and intermediates
MX9605206A (es) 1alfa,26-dihidroxi-d-homo-vitamina d3.
HU9601857D0 (en) New benzyl-piperidine- or -tetrahydro-pyridine derivatives and processes for producing them
AU7880494A (en) 5-methyluridine process for large-scale preparation of 2',3'-didehydro-3'-deoxythymidine (d4T)
MX9803672A (es) Nuevos derivados de fenilamidina, procedimiento para su preparacion y su utilizacion como medicamentos.
EP0543023A4 (en) Process for producing astaxanthin by fermentation
HU910506D0 (en) Process for producing 20, 21-dinoreburnamenine derivatives substituted inthe 9,10 and/or 11-location and pharmaceutical preparatives containing said compounds
DE59610819D1 (de) Arzneistoffe zur selektiven bekämpfung von tumorgewebe
HUP9901600A3 (en) Vitamin d analogues, their use, pharmaceutical compositions containing them, process for their production and process producing intermediates
DE3070735D1 (en) 4-aryloxy-3-phenylpiperidine derivatives, intermediates, a process for the preparation of such compounds and their use as medicaments
HU9203928D0 (en) 6-sulfonyl-substituted 3-hydroxi-chromane derivatives and pharmaceutical preparatives containing them
MX9602804A (es) Derivados del 3-aril-alquenil-1,2,4-oxadiazol y su uso como parasiticidas para animales.
AU8516991A (en) Arg a human gene related to but distinct from abl proto-oncogene
GB9100381D0 (en) Human bfgf derivatives,their analogs and process for their production
EP0641335A4 (en) SYNTHESIS OF BENZOPROSTACYCLINES CATALYZED BY FREE RADICALS.
HU910463D0 (en) Process for the production of medical preparation
HUP9600476A3 (en) Benzothiophene compounds, intermediates, process for their production, their use and compositions containing them
AU619888C (en) Alpha, alpha - disubstituted n-cycloalkylalkylbenzylamines, process for their preparation, their use as a medicament and their synthesis intermediates
AU634635C (en) 1-alkyl-, 1-alkenyl- and 1-alkynylaryl-2-amino-1,3- propanediols and related compounds, a process and intermediates for their preparation and their use as medicaments
YU16590A (en) Process for preparing cyclical derivatives of 2',3'-seco-uridine
HU903473D0 (en) Process for the production of beta-cyclodextrine based inclusion as a medical product
ZA923165B (en) Novel anthelmintic milbemycin analogs of novel microorganisms
MN426A8 (en) Preparation of lactic-acidic product vitaminized by b12 using propion-acidic p.shermani bacteria

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: CORRECTION OF THE EP APPLICATION FILING DATE FROM 07.12.2001 TO 11.04.1997.

PE Patent expired

Effective date: 20170410